抗小鼠CD40单抗（FGK45）
anti-CD40 (mouse), mAb (FGK45)
- 产品特性
- 相关资料
- Q&A
- 参考文献
anti-CD40 (mouse), mAb (FGK45)
抗小鼠CD40单抗（FGK45）
◆规格/处理
|
产品详情 |
|
|
别名 |
肿瘤坏死因子受体超家族成员5；CD40L受体 |
|
产品类型 |
单克隆抗体 |
|
属性 |
|
|
克隆 |
FGK45 |
|
同型 |
大鼠IgG2a |
|
来源/宿主 |
纯化自浓缩杂交瘤组织培养上清液 |
|
免疫原/抗体 |
重组小鼠CD40嵌合蛋白 |
|
应用 |
流式细胞术 功能应用：在体内和体外激活B细胞和NK细胞。进行细胞或体内实验时， 功能应用：建议使用不含防腐剂的抗体（产品编号：AG-20B-0036PF）。 |
|
交叉反应 |
小鼠 |
|
特异性 |
识别小鼠CD40 |
|
纯度 |
≥95% (SDS-PAGE) |
|
纯化详情 |
蛋白G亲和纯化 |
|
内毒素水平 |
<0.01 EU/μg纯化蛋白(LAL test; Lonza) |
|
浓度 |
1 mg/mL |
|
配方 |
含0.02%叠氮钠的PBS缓冲液 |
|
其他产品数据 |
广泛用于CD40的刺激性mAb。间接性激活NK细胞，产生显著的抗癌抗转移作用。 |
|
运输与处理 |
|
|
运输 |
蓄冷剂 |
|
短期储存 |
+4 °C |
|
长期储存 |
-20 °C |
|
处理建议 |
开启后，分成等分并储存在-20 °C |
|
使用/稳定性 |
在-20 °C储存条件下，稳定保存至少1年 |
◆概述
CD40属于肿瘤坏死因子受体超家族，并且在介导多种免疫和炎症反应，如T细胞依赖性抗原种类转换、记忆B细胞发育与淋巴母细胞中心形成中是必不可少的。CD40-CD40L的相互作用对于淀粉样蛋白诱导的小胶质细胞激活是必需的。因此，这也被认为是阿尔茨海默病发病机制的早期事件。CD40由抗原呈递细胞组成性表达，包括树突细胞、B细胞和巨噬细胞。与其在正常细胞上的广泛表达一致，CD40在多种肿瘤细胞上均有表达，包括非霍奇金淋巴瘤和霍奇金淋巴瘤、骨髓瘤和鼻咽癌、膀胱癌、子宫颈癌、肾癌和卵巢癌等。
◆产品列表
|
产品编号 |
产品名称 |
包装 |
|
AG-20B-0036-C100 |
anti-CD40 (mouse), mAb (FGK45) |
100 µg |
|
AG-20B-0036-C500 |
anti-CD40 (mouse), mAb (FGK45) |
500 µg |
◆相关产品
|
产品编号 |
产品名称 |
包装 |
|
ALX-522-110-C010 |
MEGACD40L (soluble) (human), (recombinant) |
10 μg |
|
ALX-522-120-C010 |
MEGACD40L (soluble) (mouse), (recombinant) |
10 μg |
|
ANC-504-020 |
CD40 (human)-muIg Fusion Protein |
25 µg |
|
AG-40B-0020-3010 |
CD40L (mouse) (multimeric) (rec.) |
3×10 µg |
|
AG-40B-0020-C010 |
CD40L (mouse) (multimeric) (rec.) |
10 µg |
|
AG-40B-0010-3010 |
CD40L (human) (multimeric) (rec.) |
3×10 µg |
|
AG-40B-0010-C010 |
CD40L (human) (multimeric) (rec.) |
10 µg |
|
AG-40B-0010B-C010 |
CD40L (human) (multimeric) (rec.) (Biotin) |
10 µg |
|
AG-40B-0010B-3010 |
CD40L (human) (multimeric) (rec.) (Biotin) |
3 ×10 µg |
|
AG-27B-6002PF-C100 |
anti-CD40L (human), mAb (rec.) (blocking) (hu5c8) (preservative free) 抗CD40L（人）单克隆抗体（重组）（封闭） （hu5c8）（不含防腐剂） |
100 µg |
|
AG-20B-0036PF-M005 |
anti-CD40 (mouse), mAb (FGK45) (preservative free) |
5 mg |
|
AG-20B-0036PF-C100 |
anti-CD40 (mouse), mAb (FGK45) (preservative free) |
100 µg |
|
AG-20B-0036PF-C500 |
anti-CD40 (mouse), mAb (FGK45) (preservative free) |
500 µg |
参考文献
|
1. |
The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching: A. Rolink, et al.; Immunity 5, 319 (1996) |
|
2. |
Characterization of immature B cells by a novel monoclonal antibody, by turnover and by mitogen reactivity: A.G. Rolink, et al.; Eur. J. Immunol. 28, 3738 (1998) |
|
3. |
Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells: J.G. Turner, et al.; J. Immunol. 166, 89 (2001) |
|
4. |
Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process: C. Mauri, et al.; Nat. Med. 6, 673 (2000) |
|
5. |
Ovarian insufficiency and early pregnancy loss induced by activation of the innate immune system: A. Erlebacher, et al.; J. Clin. Invest. 114, 39 (2004) |
|
6. |
CD154 is a negative regulator of autoaggressive CD8+ T cells in type 1 diabetes: C.M. McGregor, et al.; PNAS 101, 9345 (2004) |
|
7. |
IRF-7 is the master regulator of type-I interferon-dependent immune responses: K. Honda, et al.; Nature 434, 772 (2005) |
|
8. |
In vivo and in vitro regulation of type I IFN synthesis by synergistic effects of CD40 and type II IFN: J.A. Greene, et al.; J. Immunol. 176, 5995 (2006) |
|
9. |
IL-10- and IL-12-independent down-regulation of allergic sensitization by stimulation of CD40 signaling: P.W. Hellings, et al.; J. Immunol. 177, 5138 (2006) |
|
10. |
Agonistic Anti-CD40 Antibody Profoundly Suppresses the Immune Response to Infection with Lymphocytic Choriomeningitis Virus: C. Bartholdy, et al.; J. Immunol. 178, 1662 (2007) |
|
11. |
Excessive interferon-α signaling in autoimmunity alters glycosphingolipid processing in B cells: A. Hee-Meng Tan, et al.; J. Autoimmun. in press (2017) |